Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Allogeneic Regulatory T-Cell Immunotherapy (HSPC + T cells) |
Engineered allogeneic cell therapy — HSPC, regulatory T cells, conventional T cells | Hematologic | ||
|
Molecule
Allogeneic Regulatory T-Cell Immunotherapy (HSPC + T cells)
Therapeutic Category
Cellular Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
Engineered allogeneic cell therapy — HSPC, regulatory T cells, conventional T cells |
||||
Almonertinib (Furmonertinib) |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Almonertinib (Furmonertinib)
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Anitocabtagene Autoleucel |
Chimeric Antigen Receptor T-Cell Therapy | Hematologic (Leukemia/Lymphoma/Myeloma) | ||
|
Molecule
Anitocabtagene Autoleucel
Therapeutic Category
Cellular Therapy (CAR-T)
Oncology Type
Hematologic (Leukemia/Lymphoma/Myeloma)
Drug Class / Mechanism
Chimeric Antigen Receptor T-Cell Therapy |
||||
Anlotinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Anlotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Apatinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Apatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
APG-115 (Alrizomadlin) |
MDM2 Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
APG-115 (Alrizomadlin)
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
||||
APG-2575 (Lisaftoclax) |
BCL-2 Inhibitor | Hematologic | ||
|
Molecule
APG-2575 (Lisaftoclax)
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
||||
ARV-110 (Bavdegalutamide) |
Androgen Receptor Degrader (PROTAC) | Solid Tumour (Prostate) | ||
|
Molecule
ARV-110 (Bavdegalutamide)
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
||||
ARV-471 (Vepdegestrant) |
Androgen Receptor Degrader (PROTAC) | Solid Tumour (Prostate) | ||
|
Molecule
ARV-471 (Vepdegestrant)
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
||||
Avadomide |
IMiD (Cereblon Modulator) | Hematologic (Multiple Myeloma) | ||
|
Molecule
Avadomide
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
||||
Avapritinib |
Multi-Kinase / Anti-Angiogenic Inhibitor | Solid Tumour | ||
|
Molecule
Avapritinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
||||
Avelumab |
Anti-PD-L1 mAb | Solid Tumour | ||
|
Molecule
Avelumab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-PD-L1 mAb |
||||
Allogeneic Regulatory T-Cell Immunotherapy (HSPC + T cells)Cellular Therapy |
|
|
Therapeutic Category
Cellular Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
Engineered allogeneic cell therapy — HSPC, regulatory T cells, conventional T cells |
|
Almonertinib (Furmonertinib)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
Anitocabtagene AutoleucelCellular Therapy (CAR-T) |
|
|
Therapeutic Category
Cellular Therapy (CAR-T)
Oncology Type
Hematologic (Leukemia/Lymphoma/Myeloma)
Drug Class / Mechanism
Chimeric Antigen Receptor T-Cell Therapy |
|
AnlotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
ApatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
APG-115 (Alrizomadlin)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
MDM2 Inhibitor |
|
APG-2575 (Lisaftoclax)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
|
ARV-110 (Bavdegalutamide)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
|
ARV-471 (Vepdegestrant)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour (Prostate)
Drug Class / Mechanism
Androgen Receptor Degrader (PROTAC) |
|
AvadomideImmunomodulatory Agent |
|
|
Therapeutic Category
Immunomodulatory Agent
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
IMiD (Cereblon Modulator) |
|
AvapritinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
Multi-Kinase / Anti-Angiogenic Inhibitor |
|
AvelumabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-PD-L1 mAb |
|